Women showed consistently higher post-T2D mental health diagnoses, with the strongest signal in younger women, supporting ...

The American Academy of Neurology (AAN) and American Headache Society (AHS) issued an updated practice guideline for the ...

In "COVID-19 in 2026: Why the Virus Still Threatens Vulnerable Patients," moderator Jeff Goad, PharmD, MPH is joined by ...

Global pharmacy leaders aligned on four levers for durable primary care integration: workforce readiness, sustainable funding ...

As data reframes vaccines as a lifelong tool, pharmacists are becoming the access point that keeps patients up to date at every stage of life. Vaccination has long been framed as something completed ...

From the industry-wide efforts of major players in pharmacy to grassroots efforts at the local level, advocacy for the ...

The FDA approved tirzepatide (Mounjaro) for lowering the risk of major adverse cardiovascular events (MACE) among adults with ...

The approval gives pharmacists a new nonTNF biologic option across both major forms of pediatric inflammatory bowel disease.

Shortly after the executive order, the Department of Health and Human Services (HHS), under Secretary Robert F. Kennedy Jr, quietly posted a request for information (RFI) to seek public input on ...

Community pharmacists are on the front lines of identifying patients whose headache may actually be an undiagnosed migraine, ...

Randomization to early versus delayed LAIV enabled causal inference linking LAIV to increased pneumococcal density in ...

Chronic respiratory diseases substantially magnify pneumococcal pneumonia and invasive disease risk, with especially high CAP ...